Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status

Osimertinib, a third-generation epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated to be effective for treating patients with T790M-positive advanced non-small cell lung cancer (NSCLC) with a relatively good performance status (grade 0–1). Reports of therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishii, Yoichi, Hataji, Osamu, Ito, Kentaro, Watanabe, Fumiaki, Kobayashi, Tetsu, D’Alessandro-Gabazza, Corina, Toda, Masaaki, Taguchi, Osamu, Yamamoto, Nobuyuki, Gabazza, Esteban C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774518/
https://www.ncbi.nlm.nih.gov/pubmed/29399354
http://dx.doi.org/10.3892/mco.2017.1522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774518/
https://www.ncbi.nlm.nih.gov/pubmed/29399354
http://dx.doi.org/10.3892/mco.2017.1522

Ejemplares similares